ASTRO: Radiation Better Than Surgery at Preserving Speech for Patients With Head and Neck Cancer
Posted on: Friday, 2 December 2005, 15:00 CST
WASHINGTON, Dec. 2 /U.S. Newswire/ -- Patients suffering from advanced head and neck cancer affecting their larynx can maintain vocal function by undergoing a combination of radiation therapy and chemotherapy instead of surgery to remove the larynx, according to a study published in the Dec. 1 issue of the International Journal of Radiation Oncology - Biology - Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.
Doctors in the Department of Otolaryngology b Head and Neck Surgery at the University of Michigan in Ann Arbor, Mich., studied 97 patients with advanced laryngeal cancer. All of the patients were given an initial course of chemotherapy and depending on their response to that treatment, they either underwent a laryngectomy to remove the larynx or received radiation therapy coupled with chemotherapy.
The results showed that patients who were able to keep their larynx intact and underwent radiation therapy maintained a higher voice-related quality of life than those who had their larynx removed. While swallowing function was comparable between the two groups, understandability of speech was much better in patients who kept their larynx. In addition, 89 percent of patients with their larynx intact were able to obtain nutrition orally and without supplements, compared to 64 percent who underwent the laryngectomy. The overall three-year survival rate for all patients was 86 percent.
"Undergoing the radiation, chemotherapy combination can increase toxicity levels in some patients, but maintaining the overall quality of life for those patients justifies the potential for added toxicity," said Kevin Fung, M.D., F.R.C.S.(C)., lead author of the study and currently a Head and Neck Surgeon at the University of Western Ontario in London, Ontario, Canada. "The overall survival rate is high for both sets of patients but those patients who respond well to the initial treatments and can avoid the surgery also avoid the social, emotional and physical side effects such as cosmetic disfigurement and speech alteration."
For more information on radiation therapy for head and neck cancer, please visit http://www.rtanswers.org.
---
EDITOR'S NOTE: To arrange an interview with Dr. Fung or for a copy of "Voice and Swallowing Outcomes of an Organ-Preservation Trial for Advanced Laryngeal Cancer," please contact Nick Lashinsky at nickl(At)astro.org or 1-800-962-7876.
------
ASTRO is the largest radiation oncology society in the world, with more than 8,000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.
http://www.usnewswire.com
Source: U.S. Newswire
Related Articles
- Viventia Cancer Combination Therapy Shows Effectiveness
- Novacea's Phase 1 Data of Asentar Published in the Journal of Cancer Chemotherapy and Pharmacology
- Genmab Begins Trial of Cancer Combination Therapy
- Valeant Pharmaceuticals Announces Availability of Complimentary ``Managing Chemotherapy Side Effects For Dummies'' Cancer Chemotherapy Resource; Special Edition ``For Dummies''(R) Book Now Available for Cancer Chemotherapy Patients and Caregivers
- Avantogen Oncology Inc. Announces Preliminary Results of a Dose Ranging Study of RP101 in Combination With Gemcitabine Chemotherapy in Patients With Advanced Pancreatic Cancer
- Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In Patients With Advanced Colorectal Cancer
- Chemo, Radiation Beat Back 2nd Round of Head, Neck Cancers
- Independent Clinical Review of Phase III Trial Shows Erbitux and Radiation Control Spread of Advanced Squamous Cell Cancer of the Head and Neck Better Than Radiation Alone; Primary and Secondary Study Endpoints Met With Statistical Significance
- Inovio Biomedical and University of Southampton Collaboration: Initiation of Phase I/II Clinical Trial in Patients With Recurrent Prostate Cancer
- OvaRex MAb for Patients With Advanced Ovarian Cancer May Extend Remission Following Favorable Surgery and Chemotherapy
User Comments (0)

RSS Feeds